Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of consent form signed by at least one parent or another legally acceptable representative, and by at least one independent witness.~* Completion of vaccinations according to the national immunization schedule~* Subject and parent/legally acceptable representative able to attend all scheduled visits and comply with all trial procedures.~* Previous receipt of two doses of a mouse-brain-derived JE vaccine at 12 to 15 months of age according to the national immunization schedule and aged 2 to 5 years on the day of inclusion.~* Aged 12 to 24 months on the day of inclusion and have not received any JE vaccine.~Exclusion Criteria:~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination.~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy.~* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances.~* Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.~* Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of the immune response.~* Receipt of hepatitis A vaccine.~* History of flavivirus infection (confirmed either clinically, serologically or microbiologically).~* Administration of any anti-viral within 2 months preceding the screening visit.~* History of central nervous system disorder or disease.~* Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia.~* Planned participation in another clinical trial during the present trial period.~* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.~* Planned receipt of any vaccine in the 4 weeks following any trial vaccination.~* Personal human immunodeficiency virus, hepatitis B or hepatitis C seropositivity in the blood sample taken at screening.~* Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating IM vaccination.~* Previous vaccination against flavivirus disease at any time before the trial other than a mouse-brain-derived JE vaccine given in a two-dose regimen at 12 to 15 months of age in accordance with the national immunization schedule.~* Febrile illness or any acute illness/infection on the day of vaccination, according to investigator judgment~* History of seizures.~* Previous vaccination against flavivirus disease.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- JE-CV/Hepatitis A (Group 1) (Type: EXPERIMENTAL): Participants aged 2 to 5 years at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
- Hepatitis A/JE-CV (Group 2) (Type: EXPERIMENTAL): Participants aged 2 to 5 years at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)
- JE-CV/Hepatitis A (Group 3) (Type: EXPERIMENTAL): Participants aged 12 to 24 months at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
- Hepatitis A/JE-CV (Group 4) (Type: EXPERIMENTAL): Participants aged 12 to 24 months at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)

Based on this trial design, predict the completion outcome and termination type (if applicable).